Guided Therapeutics (GTHP) Other Non Operating Income (2013 - 2025)
Guided Therapeutics (GTHP) reported Other Non Operating Income of -$579000.0 for Q4 2025, down 87.38% on a YoY basis from -$4.6 million in Q4 2024, and down 446.23% sequentially from -$106000.0 in Q3 2025.
Guided Therapeutics (GTHP) Other Non Operating Income (2013 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 13 years of Other Non Operating Income data on file, last reported at -$579000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income fell 87.38% year-over-year to -$579000.0; the trailing twelve-month figure through Dec 2025 stood at -$523000.0 (down 30.42% YoY), and the FY2025 full-year result was -$533000.0, down 72.49% from the prior year.
- Other Non Operating Income retreated to -$579000.0 in Q4 2025, from -$106000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $555000.0 in Q3 2021 to a low of -$579000.0 in Q4 2025.
- A 5-year average of -$60388.9 and a median of $1000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income slumped 930.0% in 2024 and surged 9700.0% in 2025, its largest moves.
- Tracing GTHP's Other Non Operating Income over 5 years: stood at -$286000.0 in 2021, then jumped by 103.85% to $11000.0 in 2022, then plunged by 372.73% to -$30000.0 in 2023, then tumbled by 930.0% to -$309000.0 in 2024, then tumbled by 87.38% to -$579000.0 in 2025.
- Business Quant data shows GTHP's Other Non Operating Income at -$579000.0 in Q4 2025, -$106000.0 in Q3 2025, and $64000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.21 Bn | 176.92 Bn | 6.27 Bn |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn |
| 3 | Medtronic | 109.00 Bn | 99.78 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.62 Bn | 67.16 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.39 Bn | 43.72 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.44 Bn | 26.16 Bn | 1.98 Bn |
| 7 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 27.03 Bn | 26.46 Bn | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.43 Bn | 2.07 Bn |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -579,000.00 |
| Sep 30, 2025 | -106,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | -309,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Sep 30, 2023 | 17,000.00 |
| Jun 30, 2023 | 17,000.00 |
| Dec 31, 2022 | 11,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | -64,000.00 |
| Dec 31, 2021 | -286,000.00 |
| Sep 30, 2021 | 555,000.00 |
| Jun 30, 2021 | -473,000.00 |
| Mar 31, 2021 | 87,000.00 |
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 20,000.00 |